RBC Capital Reiterates Sector Perform on Neurocrine Biosciences, Maintains $133 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated a Sector Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $133.
October 08, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating for Neurocrine Biosciences, maintaining a price target of $133. This suggests a neutral outlook on the stock's performance.
The reiteration of a Sector Perform rating and maintenance of the price target at $133 by RBC Capital indicates a neutral stance on NBIX. This suggests that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100